CytoSorbents Corporation (CTSO)

[alexander77]

Updates: CytoSorbents Executive Summary -June 2010 and CytoSorbents Company Presentation -June 2010

http://02c390e.netsolhost.com/invest.htm

keywords:
limited competition (only Xigris is approved to treat sepsis, but has questionable efficacy and safety)
critical care play and therefore an easy market penetration
reimbursement friendly
high margin disposable device in an under-served multi-billion dollar market with strategically important technology



The Company has leading, patented technology backed by strong science and a highly profitable business model. We believe CytoSorb™ has the potential to be a blockbuster therapy that can be sold throughout the world as a treatment for sepsis and other diseases exacerbated by cytokine storm. If successful, these characteristics position the Company well for growth and future value creation for shareholders. Also, we continue to unlock the value of our underlying polymer platform technology through the ability to modify it for other medical applications, further broadening our pipeline and potential for out-licensing opportunities.